<DOC>
	<DOCNO>NCT00528333</DOCNO>
	<brief_summary>The purpose study ass whether survival benefit lintuzumab give combination low dose cytarabine versus low dose cytarabine placebo patient AML .</brief_summary>
	<brief_title>A Study Lintuzumab ( SGN-33 ) Combination With Low Dose Cytarabine Patients 60+ Years With AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Untreated AML occur de novo , prior exposure chemotherapy separate malignancy , evolve antecedent hematologic disorder . After inform potential benefit risk available treatment option , patient must decline intensive chemotherapy AML . At least 20 % blast blood marrow . Must minimum 50 % leukemic blast express CD33 . ECOG performance status score 0 2 . WBC le 30,000/ÂµL No know diagnosis acute promyelocytic leukemia chronic myeloid leukemia . No active systemic malignancy treat chemotherapy within last 12 month . Must receive previous chemotherapy ( except hydroxyurea ) AML . Must significantly abnormal kidney liver disease . Must know human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Lintuzumab</keyword>
	<keyword>Antigens , CD33</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Leukemia</keyword>
</DOC>